|
Market Closed -
Toronto S.E.
00:59:58 19/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.620 CAD | -3.15% |
|
-10.30% | +8.84% |
Company Valuation: Satellos Bioscience Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6.794 | 36.73 | 95.65 | 89.3 | 127.6 | - | - |
| Change | - | 440.53% | 160.46% | -6.65% | 42.9% | - | - |
| Enterprise Value (EV) 1 | 6.794 | 36.73 | 46.68 | 89.3 | 84.91 | 5.057 | -59.59 |
| Change | - | 440.53% | 27.11% | 91.29% | -4.91% | -94.04% | -1,278.32% |
| P/E | -0.69x | -2.39x | -3.32x | -3.36x | -2.8x | -2.59x | -2.67x |
| PBR | - | - | - | - | 3.27x | 3.23x | - |
| PEG | - | 0.1x | -0.1x | 0.2x | -0.1x | -0.33x | 0.97x |
| Capitalization / Revenue | - | - | - | - | - | - | 11x |
| EV / Revenue | - | - | - | - | - | - | -5.13x |
| EV / EBITDA | - | - | - | -3.38x | -3.4x | -0.18x | 2.13x |
| EV / EBIT | -1.08x | -3.23x | -2.4x | -3.37x | -1.85x | -0.09x | 0.85x |
| EV / FCF | - | - | -2.67x | - | -2.35x | -0.12x | - |
| FCF Yield | - | - | -37.5% | - | -42.6% | -867% | - |
| Dividend per Share 3 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 3 | -3.84 | -2.16 | -3 | -2.354 | -3.081 | -3.323 | -3.231 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | 11.61 |
| EBITDA 1 | - | - | - | -26.46 | -25 | -27.75 | -28 |
| EBIT 1 | -6.268 | -11.38 | -19.45 | -26.46 | -45.81 | -59.48 | -70.43 |
| Net income 1 | -8.368 | -11.69 | -19.65 | -24.87 | -44.03 | -66.91 | -81.73 |
| Net Debt 1 | - | - | -48.97 | - | -42.7 | -122.6 | -187.2 |
| Reference price 3 | 2.640 | 5.160 | 9.960 | 7.920 | 8.620 | 8.620 | 8.620 |
| Nbr of stocks (in thousands) | 3,483 | 9,399 | 13,818 | 15,459 | 21,216 | - | - |
| Announcement Date | 30/03/23 | 27/03/24 | 26/03/25 | 27/03/26 | - | - | - |
1CAD in Million2USD in Million3CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.8x | - | -3.4x | - | 128M | ||
| 17.09x | 6.54x | 12.53x | 1.75% | 65.45B | ||
| 31.87x | 8.51x | 28.12x | 0.07% | 58.93B | ||
| 38.62x | 6.88x | 20.56x | 0.84% | 55.21B | ||
| 43.31x | 6.04x | 28.76x | -.--% | 46.1B | ||
| 33.65x | 3.22x | 13.91x | -.--% | 42.49B | ||
| 35.05x | 8.68x | 22.64x | 0.37% | 35.56B | ||
| -18.94x | 54.62x | -20.7x | -.--% | 34.57B | ||
| 41.52x | 8.01x | 26.86x | -.--% | 32.46B | ||
| -74.21x | 13.84x | -79.52x | -.--% | 26.28B | ||
| Average | 14.52x | 12.93x | 4.98x | 0.34% | 40B | |
| Weighted average by Cap. | 21.51x | 11.45x | 11.08x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MSCL Stock
- Valuation Satellos Bioscience Inc.
Select your edition
All financial news and data tailored to specific country editions
















